In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Growth

Set Alert for Growth

New Science As A Business Growth Strategy

Finding innovative ways to adapt the biopharma business model to external and internal challenges is a key competitive differentiator for today’s C-suite leadership. 

Business Strategies Growth Research and Development Strategies

Latest From Growth

Immuno-Oncology Continues To Draw Pharma Companies To The Deal Table

Immuno-oncology development trends are revealed through an analysis of deals between cancer drug developers over the past five years.

BioPharmaceutical Deals

Changing China Is Opening Up For Health Care Entrants

The potential of China’s vast health care products market is alluring. It has proved off-limits to most of the global medtech industry, and is rarely in the early launch strategies of global companies. Government-led initiatives want that to change, as evidenced in the latest Five-Year Plan and the recent Healthy China 2030 report.

Outlook 2020 Asia Pacific

Taking Aim At Advanced Therapies

Dmitry Kuzmin, managing partner, and Owen Smith, investment director, talk to In Vivo about 4BIO’s approach to venture investing in the biopharma sector: successes, red flags and targets for its second fund.

VC Playbook Business Strategies

Denmark Offers One-Stop-Shop For Clinical Trials

Denmark’s Trial Nation Portal was established in 2018 with government backing and the aim of luring clinical trials to the country. 

Denmark Sweden

PureTech’s Problem-Solving Skills Target The BIG Picture

PureTech Health has amassed niche expertise and built a unique structure that allows it to develop technologies for unmet needs, in the separate but related areas of brain-immune-gut. And now, with the experienced ex-Sanofi CEO Chris Viehbacher as interim chair, PureTech can target a smooth path to its next growth stages in the “BIG Axis.” Senior executives Eric Elenko and Joep Muijrers reveal more about the focus and aims of the Boston, US group.

C-Suite Speaks Business Strategies

MorphoSys: A European Champion Crossing The Biopharma Rubicon

The Munich-based company is one of a handful of mature European biotechs poised to enter the big league. New CEO Jean-Paul Kress talks to In Vivo about the firm’s next generation antibody platform and why US expansion is crucial to its future.

BioPharmaceutical C-Suite Speaks
See All
UsernamePublicRestriction

Register